|
Hyperalgesia
|
0.510 |
AlteredExpression
|
phenotype |
BEFREE |
Topiramate treatment prevented NTG-induced changes by reversing NTG-induced hyperalgesia and allodynia, and inhibiting CGRP and c-Fos gene expression in all areas evaluated.
|
30003352 |
2018 |
|
Hyperalgesia
|
0.510 |
Biomarker
|
phenotype |
CTD_human |
Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK.
|
27093858 |
2016 |
|
Hypertensive disease
|
0.510 |
Biomarker
|
group |
CTD_human |
Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-γ expression and suppressing AP-1 activity.
|
24039778 |
2013 |
|
Hyperalgesia
|
0.510 |
Biomarker
|
phenotype |
RGD |
Vesicular glutamate transporter-3 contributes to visceral hyperalgesia induced by Trichinella spiralis infection in rats.
|
22160634 |
2012 |
|
Hypertensive disease
|
0.510 |
GeneticVariation
|
group |
BEFREE |
In conclusion, diverse binding affinities of YY1 and its interacting partners to iNOS -1026C/A resulted in differential promoter activity, and potent inhibition of iNOS expression by YY1/AP-1 complex with -1026C may contribute to an enhanced risk for hypertension.
|
20430007 |
2010 |
|
Hypertensive disease
|
0.510 |
Biomarker
|
group |
RGD |
Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats.
|
16696897 |
2006 |
|
Hypertensive disease
|
0.510 |
Biomarker
|
group |
CTD_human |
Down-regulation of basal Fos expression at nucleus tractus solitarii underlies restoration of baroreflex response after antihypertensive treatment in spontaneously hypertensive rats.
|
12044476 |
2002 |
|
Reperfusion Injury
|
0.500 |
Biomarker
|
disease |
RGD |
Temporal and regional expression of Fos-related proteins in response to ischemic injury.
|
15121240 |
2004 |
|
Reperfusion Injury
|
0.500 |
Biomarker
|
disease |
CTD_human |
Differential expression of c-jun, c-fos and hsp 70 mRNAs after folic acid and ischemia-reperfusion injury: effect of antioxidant treatment.
|
7922267 |
1994 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with control, expressions of the TF genes EGR1, FOS and ETS2 were all up-regulated in the HCC cell line, HepG2; while LEF1 was down-regulated.
|
28043148 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome.
|
30013671 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome.
|
30013671 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Liver-enriched activator protein 1 as an isoform of CCAAT/enhancer-binding protein beta suppresses stem cell features of hepatocellular carcinoma.
|
29731667 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study demonstrated that <i>FOS</i>, <i>DDIT3</i>, the cytokine-cytokine receptor interaction pathway and the chemokine signaling pathway may be key genes and pathways associated with the development of HCC.
|
29434983 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we speculated that miR-181a-5p, which was upregulated in HCC tissues, could regulate FOS and EGR1 to promote the invasion and progression of HCC by p53 signaling pathway.
|
30228980 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An inverse correlation between c-FOS and the LXRα pathway was also observed in human HCC cell lines and datasets.
|
28356389 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The FN1, IL6 and FOS genes may therefore be potential targets in the treatment of breast cancer.
|
25824986 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The FN1, IL6 and FOS genes may therefore be potential targets in the treatment of breast cancer.
|
25824986 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.
|
25526895 |
2015 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The present study established that the signaling mechanism underlying the AA-dependent transcriptional regulation of the cFOS gene in HepG2 human hepatocellular carcinoma cells is independent of the classic GCN2-eIF2-ATF4 pathway.
|
25523140 |
2015 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among them, one novel SNP was found in activator protein-1 (AP2), a transcription factor binding site (-483 A to C) that may be associated with the susceptibility to HCC (P = 0.012) but no associations were found for other observed variations.This mutation could be tumor-specific.
|
24659263 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the potential role of AP-1 family members as novel biomarkers in breast cancer.
|
24073962 |
2013 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Νuclear factor-κB (NF-κB) and activator protein-1 (AP-1) are major transcription factors that have been associated with breast cancer metastasis by inducing matrix metalloproteinase-9 (MMP-9) expression.
|
23242121 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Νuclear factor-κB (NF-κB) and activator protein-1 (AP-1) are major transcription factors that have been associated with breast cancer metastasis by inducing matrix metalloproteinase-9 (MMP-9) expression.
|
23242121 |
2013 |